BASILEA N | 40,200 / +0,50% |
Datum/Vreme | 30.06. / 09:30 |
Promena / Promena(%) | 0,200 / +0,50% |
Tražnja | 40,150 / 100 |
Ponuda | 40,450 / 70 |
Cena na otvaranju | 40,000 |
Prethodno zatvaranje | 40,000 |
Najviša cena | 40,200 |
Najniža | 39,550 |
Obim [CHF] | 123.550,650 |
Obim [Jedinice] | 3.092 |
Dogovorena cena | 29 |
ISIN | CH0011432447 |
Simbol | BSLN |
Berza | SIX Swiss Exchange |
Vrsta | Stock |
Berza | Poslednja cena | Obim | |
---|---|---|---|
SIX Swiss Ex.. | 40,200 | ![]() |
3.092 |
London Domes.. | 39,70 | ![]() |
53 |
Lang & Schwa.. | 40,20 | ![]() |
|
Turquoise | 39,65 | ![]() |
858 |
Cboe Europe .. | 39,90 | 837 | |
Cboe Europe .. | 39,90 | 518 | |
Nasdaq Other.. | 41,0000 | 40 | |
München | 32,300 | 0 | |
Berlin | 32,100 | 0 | |
Frankfurt | 32,2800 | 0 | |
gettex | 32,340 | ||
TradeGate | 30,300 | 33 | |
EUREX | Opcije |
Vesti
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire